
ANRO Stock Forecast & Price Target
ANRO Analyst Ratings
Bulls say
Alto Neuroscience is expanding its pipeline and pursuing multiple avenues for potential market entry, including its ALTO-207 drug for TRD which has a higher chance of success and potential for a broader label due to its fixed-dose combination and positive safety profile. The company also plans to initiate a Phase 3 monotherapy trial for ALTO-207 in TRD in 2H27, which could accelerate the path to potential approval. In addition to its strong pipeline, Alto Neuroscience's precision approach to drug development utilizing biomarkers adds potential for higher success rates and can potentially enhance the company's valuation.
Bears say
Alto Neuroscience is facing steep losses with negative GAAP EPS and will require additional financing given their low cash reserves, resulting in an extended cash runway but also requiring a decrease in valuation discount rate. Despite pipeline advancements, more clinical data is needed for clarity on profit potential, leading to a Neutral rating and a lower target price.
This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.
ANRO Analyst Forecast & Price Prediction
Start investing in ANRO
Order type
Buy in
Order amount
Est. shares
0 shares